The podcast discusses the revenue of pharmaceutical and medtech companies in 2025. Pfizer will reach more than $63 billion in revenue in 2024, representing a year-over-year increase of 7 percent. The firm expects 2025 revenue in the range of $61 billion to $64 billion and adjusted earnings of $2.8 to $3 per share[1][2][4]. Eli Lilly posted revenue of more than $45 billion in 2024, up 32 percent, and projects revenue of $58 billion to $61 billion in 2025[2]. AstraZeneca reported revenue of $58.7 billion in 2025, a growth of 9 percent[7]. Novo Nordisk expects sales to increase by 16 to 24 percent and operating profit by 19 to 27 percent in 2025[2].